DRUG-INDUCED ENCEPHALOPATHY WITH IMPAIRED COGNITIVE FUNCTIONS DURING TOCILIZUMAB USE
https://doi.org/10.14412/1995-4484-2019-482-485
Abstract
Blockade of interleukin-6 (IL-6) is one of the most promising areas in the treatment of a number of immunoinflammatory diseases. Tocilizumab (TCZ), the first registered anti-IL-6 receptor monoclonal antibody, has been used effectively by rheumatologists since 2010. During this period, the spectrum of adverse reactions (ARs) of TCZ has been clearly defined. However, the multifaceted biological effects of IL-6 determine the probability of unexpected ARs. The article describes a clinical case of drug-induced encephalopathy with cognitive dysfunction during TCZ therapy.
About the Authors
P. A. Shesternya
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
Russian Federation
Russian Federation
1, Partisan Zheleznyak St., Krasnoyarsk 660022
S. V. Prokopenko
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
Russian Federation
1, Partisan Zheleznyak St., Krasnoyarsk 660022
Russian Federation
1, Partisan Zheleznyak St., Krasnoyarsk 660022
E. Yu. Mozheiko
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
Russian Federation
1, Partisan Zheleznyak St., Krasnoyarsk 660022
Russian Federation
1, Partisan Zheleznyak St., Krasnoyarsk 660022
O. D. Gritsenko
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
Russian Federation
1, Partisan Zheleznyak St., Krasnoyarsk 660022
Russian Federation
1, Partisan Zheleznyak St., Krasnoyarsk 660022
T. V. Tupaeva
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
Russian Federation
1, Partisan Zheleznyak St., Krasnoyarsk 660022
Russian Federation
1, Partisan Zheleznyak St., Krasnoyarsk 660022
E. M. Kurts
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
Russian Federation
1, Partisan Zheleznyak St., Krasnoyarsk 660022
Russian Federation
1, Partisan Zheleznyak St., Krasnoyarsk 660022
References
1. Beketova TV, Nasonov EL. Innovative treatments for Takayasu’s arteritis: A focus on interleukin-6 inhibitors. The authors’ experience with tocilizumab and a review of literature. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(5):536-48 (In Russ.). doi: 10.14412/1995-4484-2017-536-548
2. http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=fbdd2232-bb05-43cf-b788-c3a1d696170c&t
3. Novikov PI, Moiseev SV. Anti-interleukin-6 therapy in rheumatoid arthritis. Klinicheskaya Farmakologiya i Terapiya = Clin Pharmacol Ther. 2016;25(3):53-8 (In Russ.).
4. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf
5. Nasonov EL, Lila AM. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: achievements, prospects, and hopes. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):590-9 (In Russ.). doi: 10.14412/1995-4484-2017-590-599
6. Beketova TV, Nasonov EL. Innovative treatments for Takayasu’s arteritis: A focus on interleukin-6 inhibitors. The authors’ experience with tocilizumab and a review of literature. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(5):536-48 (In Russ.). doi: 10.14412/1995-4484-2017-536-548
7. Curtis JR, Perez-Gutthann S, Suissa S, et al. Tocilizumab in rheumatoid arthritis: A case study of safety evaluations of a large postmarketing data set from multiple data sources. Semin Arthritis Rheum. 2015 Feb;44(4):381-8. doi: 10.1016/j.semarthrit.2014.07.006
8. Novikov PI, Moiseev SV. Anti-interleukin-6 therapy in rheumatoid arthritis. Klinicheskaya Farmakologiya i Terapiya = Clin Pharmacol Ther. 2016;25(3):53-8 (In Russ.).
9. Nasonov EL, Stanislav ML, Mazurov VI, et al. Long-term safety and efficacy of tocilizumab in patients with early rheumatoid arthritis of moderate or high activity (results of Phase III multicenter extension clinical study ML28124). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):280-5 (In Russ.). doi: 10.14412/1995-4484-2018-280-285
10. Nasonov EL, Lila AM. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: achievements, prospects, and hopes. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):590-9 (In Russ.). doi: 10.14412/1995-4484-2017-590-599
11. Jones G, Panova E. New insights and long-term safety of tocilizumab in rheumatoid arthritis. Ther Adv Musculoskel Dis. 2018;10(10):195-9. doi: 10.1177/1759720X18798462
12. Curtis JR, Perez-Gutthann S, Suissa S, et al. Tocilizumab in rheumatoid arthritis: A case study of safety evaluations of a large postmarketing data set from multiple data sources. Semin Arthritis Rheum. 2015 Feb;44(4):381-8. doi: 10.1016/j.semarthrit.2014.07.006
13. Iannone F, Ferraccioli G, Sinigaglia L, et al. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA. Clin Rheumatol. 2018 Feb;37(2):315-21. doi: 10.1007/s10067-017-3846-8
14. Nasonov EL, Stanislav ML, Mazurov VI, et al. Long-term safety and efficacy of tocilizumab in patients with early rheumatoid arthritis of moderate or high activity (results of Phase III multicenter extension clinical study ML28124). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):280-5 (In Russ.). doi: 10.14412/1995-4484-2018-280-285
15. McAfoose J, Baune BT. Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev. 2009;33:355-66.
16. Jones G, Panova E. New insights and long-term safety of tocilizumab in rheumatoid arthritis. Ther Adv Musculoskel Dis. 2018;10(10):195-9. doi: 10.1177/1759720X18798462
17. Gruol DL. IL-6 regulation of synaptic function in the CNS. Neuropharmacology. 2015 Sep;96:42-54. doi: 10.1016/j.neuropharm. 2014.10.023
18. Iannone F, Ferraccioli G, Sinigaglia L, et al. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA. Clin Rheumatol. 2018 Feb;37(2):315-21. doi: 10.1007/s10067-017-3846-8
19. Levin SG, Godukhin OV. Modulating effect of cytokines on mechanisms of synaptic plasticity in the brain. Biokhimiya = Biochemisry. 2017;82(3):397-409 (In Russ.). doi: 10.1134/S000629791703004X
20. McAfoose J, Baune BT. Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev. 2009;33:355-66.
21. Pranzatelli MR. Advances in biomarker-guided therapy for pediatric- and adult-onset neuroinflammatory disorders: targeting chemokines/cytokines. Front Immunol. 2018 Apr;4(9):557. doi: 10.3389/fimmu.2018.00557
22. Gruol DL. IL-6 regulation of synaptic function in the CNS. Neuropharmacology. 2015 Sep;96:42-54. doi: 10.1016/j.neuropharm. 2014.10.023
23. Murashko MA, Kostenko VV, Glagolev SV, et al. Monitoring bezopasnosti lekarstvennykh preparatov v voprosakh i otvetakh. Broshyura dlya spetsialistov zdravookhraneniya [Monitoring drug safety in questions and answers. Health Care Brochure]. 2014. Available from: http://www.roszdravnadzor.ru/i/upload/images/2014/12/2/1417522012.38688-1-10261.pdf (In Russ.)].
24. Levin SG, Godukhin OV. Modulating effect of cytokines on mechanisms of synaptic plasticity in the brain. Biokhimiya = Biochemisry. 2017;82(3):397-409 (In Russ.). doi: 10.1134/S000629791703004X
25. Kobayashi K, Okamoto Y, Inoue H, et al. Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA). Inter Med. 2009;48:1307-9. doi: 10.2169/internalmedicine.48.192
26. Pranzatelli MR. Advances in biomarker-guided therapy for pediatric- and adult-onset neuroinflammatory disorders: targeting chemokines/cytokines. Front Immunol. 2018 Apr;4(9):557. doi: 10.3389/fimmu.2018.00557
27. Lisitsyna TA, Veltishchev DYu, Nasonov EL. Stressors and depressive disorders in rheumatic diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(2):98-103 (In Russ.)]. doi: 10.14412/1995-4484-2013-634
28. Murashko MA, Kostenko VV, Glagolev SV, et al. Monitoring bezopasnosti lekarstvennykh preparatov v voprosakh i otvetakh. Broshyura dlya spetsialistov zdravookhraneniya [Monitoring drug safety in questions and answers. Health Care Brochure]. 2014. Available from: http://www.roszdravnadzor.ru/i/upload/images/2014/12/2/1417522012.38688-1-10261.pdf (In Russ.)].
29. Yoon B, Lee JH, Shin SY. Discrepancy between subjective and objective measures of cognitive impairment in patients with rheumatoid arthritis. Rheumatol Int. 2017;37(10):1635-41. doi: 10.1007/s00296-017-3806-2
30. Kobayashi K, Okamoto Y, Inoue H, et al. Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA). Inter Med. 2009;48:1307-9. doi: 10.2169/internalmedicine.48.192
31. Lisitsyna TA, Veltishchev DYu, Nasonov EL. Stressors and depressive disorders in rheumatic diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(2):98-103 (In Russ.)]. doi: 10.14412/1995-4484-2013-634
32. Yoon B, Lee JH, Shin SY. Discrepancy between subjective and objective measures of cognitive impairment in patients with rheumatoid arthritis. Rheumatol Int. 2017;37(10):1635-41. doi: 10.1007/s00296-017-3806-2
Review
For citations:
Shesternya P.A., Prokopenko S.V., Mozheiko E.Yu., Gritsenko O.D., Tupaeva T.V., Kurts E.M. DRUG-INDUCED ENCEPHALOPATHY WITH IMPAIRED COGNITIVE FUNCTIONS DURING TOCILIZUMAB USE. Rheumatology Science and Practice. 2019;57(4):482-485. (In Russ.) https://doi.org/10.14412/1995-4484-2019-482-485
Views:
768
Email this article 